Vicore Pharma Holding AB
STO:VICO

Watchlist Manager
Vicore Pharma Holding AB Logo
Vicore Pharma Holding AB
STO:VICO
Watchlist
Price: 8.02 SEK -0.74% Market Closed
Market Cap: 1.9B SEK
Have any thoughts about
Vicore Pharma Holding AB?
Write Note

Intrinsic Value

The intrinsic value of one VICO stock under the Base Case scenario is 2.89 SEK. Compared to the current market price of 8.02 SEK, Vicore Pharma Holding AB is Overvalued by 64%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

VICO Intrinsic Value
2.89 SEK
Overvaluation 64%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Vicore Pharma Holding AB

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for VICO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about VICO?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Vicore Pharma Holding AB

Provide an overview of the primary business activities
of Vicore Pharma Holding AB.

What unique competitive advantages
does Vicore Pharma Holding AB hold over its rivals?

What risks and challenges
does Vicore Pharma Holding AB face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Vicore Pharma Holding AB.

Provide P/S
for Vicore Pharma Holding AB.

Provide P/E
for Vicore Pharma Holding AB.

Provide P/OCF
for Vicore Pharma Holding AB.

Provide P/FCFE
for Vicore Pharma Holding AB.

Provide P/B
for Vicore Pharma Holding AB.

Provide EV/S
for Vicore Pharma Holding AB.

Provide EV/GP
for Vicore Pharma Holding AB.

Provide EV/EBITDA
for Vicore Pharma Holding AB.

Provide EV/EBIT
for Vicore Pharma Holding AB.

Provide EV/OCF
for Vicore Pharma Holding AB.

Provide EV/FCFF
for Vicore Pharma Holding AB.

Provide EV/IC
for Vicore Pharma Holding AB.

Show me price targets
for Vicore Pharma Holding AB made by professional analysts.

What are the Revenue projections
for Vicore Pharma Holding AB?

How accurate were the past Revenue estimates
for Vicore Pharma Holding AB?

What are the Net Income projections
for Vicore Pharma Holding AB?

How accurate were the past Net Income estimates
for Vicore Pharma Holding AB?

What are the EPS projections
for Vicore Pharma Holding AB?

How accurate were the past EPS estimates
for Vicore Pharma Holding AB?

What are the EBIT projections
for Vicore Pharma Holding AB?

How accurate were the past EBIT estimates
for Vicore Pharma Holding AB?

Compare the revenue forecasts
for Vicore Pharma Holding AB with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Vicore Pharma Holding AB and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Vicore Pharma Holding AB against its competitors.

Analyze the profit margins
(gross, operating, and net) of Vicore Pharma Holding AB compared to its peers.

Compare the P/E ratios
of Vicore Pharma Holding AB against its peers.

Discuss the investment returns and shareholder value creation
comparing Vicore Pharma Holding AB with its peers.

Analyze the financial leverage
of Vicore Pharma Holding AB compared to its main competitors.

Show all profitability ratios
for Vicore Pharma Holding AB.

Provide ROE
for Vicore Pharma Holding AB.

Provide ROA
for Vicore Pharma Holding AB.

Provide ROIC
for Vicore Pharma Holding AB.

Provide ROCE
for Vicore Pharma Holding AB.

Provide Gross Margin
for Vicore Pharma Holding AB.

Provide Operating Margin
for Vicore Pharma Holding AB.

Provide Net Margin
for Vicore Pharma Holding AB.

Provide FCF Margin
for Vicore Pharma Holding AB.

Show all solvency ratios
for Vicore Pharma Holding AB.

Provide D/E Ratio
for Vicore Pharma Holding AB.

Provide D/A Ratio
for Vicore Pharma Holding AB.

Provide Interest Coverage Ratio
for Vicore Pharma Holding AB.

Provide Altman Z-Score Ratio
for Vicore Pharma Holding AB.

Provide Quick Ratio
for Vicore Pharma Holding AB.

Provide Current Ratio
for Vicore Pharma Holding AB.

Provide Cash Ratio
for Vicore Pharma Holding AB.

What is the historical Revenue growth
over the last 5 years for Vicore Pharma Holding AB?

What is the historical Net Income growth
over the last 5 years for Vicore Pharma Holding AB?

What is the current Free Cash Flow
of Vicore Pharma Holding AB?

Discuss the annual earnings per share (EPS)
trend over the past five years for Vicore Pharma Holding AB.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Vicore Pharma Holding AB

Current Assets 478.2m
Cash & Short-Term Investments 466.4m
Receivables 1.6m
Other Current Assets 10.1m
Non-Current Assets 565k
PP&E 10k
Intangibles 555k
Current Liabilities 39.9m
Accounts Payable 18.2m
Accrued Liabilities 17.1m
Other Current Liabilities 4.7m
Non-Current Liabilities 3.8m
Other Non-Current Liabilities 3.8m
Efficiency

Earnings Waterfall
Vicore Pharma Holding AB

Revenue
104.2m SEK
Operating Expenses
-329.8m SEK
Operating Income
-225.6m SEK
Other Expenses
25.5m SEK
Net Income
-200.1m SEK

Free Cash Flow Analysis
Vicore Pharma Holding AB

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

VICO Profitability Score
Profitability Due Diligence

Vicore Pharma Holding AB's profitability score is 18/100. The higher the profitability score, the more profitable the company is.

18/100
Profitability
Score

Vicore Pharma Holding AB's profitability score is 18/100. The higher the profitability score, the more profitable the company is.

VICO Solvency Score
Solvency Due Diligence

Vicore Pharma Holding AB's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
69/100
Solvency
Score

Vicore Pharma Holding AB's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

VICO Price Targets Summary
Vicore Pharma Holding AB

Wall Street analysts forecast VICO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VICO is 29.65 SEK with a low forecast of 15.15 SEK and a high forecast of 40.86 SEK.

Lowest
Price Target
15.15 SEK
89% Upside
Average
Price Target
29.65 SEK
270% Upside
Highest
Price Target
40.86 SEK
410% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for VICO?

Click here to dive deeper.

Dividends

Vicore Pharma Holding AB
does not pay dividends
Shareholder Yield

Current shareholder yield for VICO is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Vicore Pharma Holding AB Logo
Vicore Pharma Holding AB

Country

Sweden

Industry

Biotechnology

Market Cap

1.9B SEK

Dividend Yield

0%

Description

Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2015-12-10. The firm's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The firm is a wholly owned subsidiary of Mintage Scientific AB.

Contact

VASTRA GOTALANDS
Goeteborg
Kronhusgatan 11
+46317880560
vicorepharma.com

IPO

2015-12-10

Employees

23

Officers

Chief Executive Officer
Mr. Ahmed S. Mousa J.D.
Chief Financial Officer
Mr. Hans Jeppsson Ph.D.
Vice President of Operations & Corporate Strategy
Mr. Mikael NygĂĄrd
Chief Scientific Officer
Dr. Johan Raud Ph.D.
Chief Administrative Officer
Ms. Nina Carlen
VP of Investor Relations, Communications & Portfolio Strategy
Ms. Megan Richards
Show More
Head of Digital Therapeutics & Director of Digital Innovation
Ms. Jessica Shull
Chief Engagement & Commercial Officer
Ms. Asa Magnusson
Chief Medical Officer
Prof. Bertil Lindmark M.D., Ph.D.
Vice President of Business Development
Mr. Jimmie Hofman
Show Less

See Also

Discover More
What is the Intrinsic Value of one VICO stock?

The intrinsic value of one VICO stock under the Base Case scenario is 2.89 SEK.

Is VICO stock undervalued or overvalued?

Compared to the current market price of 8.02 SEK, Vicore Pharma Holding AB is Overvalued by 64%.

Back to Top